Clinical Trial Update: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Denikitug (GS-1811) alone or with nivolumab or chemotherapy in adults with metastatic gastric, gastroesophageal junction, or e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Cancer

Drugs mentioned

• Denikitug (GS-1811)
• nivolumab (nivolumab)

Snippet

Sponsor: Gilead Sciences | Conditions: HER2-negative, Gastroesophageal Junction | Phase 2 | Status: NOT_YET_RECRUITING